H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions.
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; pharmaceutical scheduling; PBM reform; S.891, Bipartisan Health Care Act, improvements to the 340B drug discount program; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; drug pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation. Issues related to pharmaceutical intellectual property; HR 6130 / S 3267, the ASAP Act; legislation pertaining to cognitive assessments in Medicare.
Issues related to tax reform; R&D tax credit; Section 899; H.R.1, One Big Beautiful Bill Act.
Issues related to supply chain and tariffs. Section 232 tariff investigation on branded pharmaceuticals.